Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus
Ultragenyx shares slipped 0.2% to $22.74 premarket Wednesday after plunging 43.5% Monday on failed Phase 3 trial results for setrusumab in osteogenesis imperfecta. The company said it will cut expenses and shift focus to its DTX401 gene therapy, for which it completed a rolling FDA application. Senior VP Theodore Huizenga sold 85 shares on Dec. 29 to cover taxes. Investors await further details on cost reductions and regulatory milestones.
